Compare Neurocrine Biosciences Inc (NBIX) vs Zscaler Inc (ZS) Price & Performance

Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.

NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.

Zscaler (ZS) trades at $230.23, up 7.81% in the last 24 hours, with a bullish technical signal from moving averages. The company reported strong revenue growth, reaching $2.67 billion in 2025, and has beaten EPS estimates for three consecutive quarters. However, it remains unprofitable with a net income margin of -1.88%. Recent news includes a CRO transition and an upcoming Investor Day on October 6, 2026.

The outlook is mixed: robust revenue growth and AI-driven bookings offer upside, but profitability concerns and high valuation multiples pose risks. Analyst consensus is bullish with a $222.83 price target, though the stock trades above this level. Key risks include execution challenges and competitive pressures in cybersecurity.